Oxford Biomedica (OXB) Insider Trading & Ownership GBX 465.87 +1.37 (+0.29%) As of 12:40 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock Oxford Biomedica (LON:OXB) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage21.17%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)£36.90KNumber OfInsiders Selling(Last 12 Months)0 Get OXB Insider Trade Alerts Want to know when executives and insiders are buying or selling Oxford Biomedica stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address OXB Insider Buying and Selling by Quarter Oxford Biomedica Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/17/2025Heather PrestonInsiderBuy11,389GBX 324£36,900.36 (Data available from 1/1/2013 forward) OXB Insider Trading Activity - Frequently Asked Questions Who is on Oxford Biomedica's Insider Roster? The list of insiders at Oxford Biomedica includes Catherine Moukheibir, Dame Kay Davies, Heather Preston, Michael Hayden, and Roch Doliveux. Learn more on insiders at OXB. What percentage of Oxford Biomedica stock is owned by insiders? 21.17% of Oxford Biomedica stock is owned by insiders. Learn more on OXB's insider holdings. Which Oxford Biomedica insiders have been buying company stock? The following insiders have purchased OXB shares in the last 24 months: Dame Kay Davies (£2,910), Heather Preston (£36,900.36), Michael Hayden (£19,300), and Roch Doliveux (£98,996.20). How much insider buying is happening at Oxford Biomedica? Insiders have purchased a total of 58,519 OXB shares in the last 24 months for a total of £158,106.56 bought. Oxford Biomedica Key ExecutivesMr. Stuart Paynter (Age 52)CFO & Director Compensation: $832kDr. Frank Mathias (Age 62)CEO & Director Mr. Thierry CournezCOO & Oxford Site HeadDr. James Miskin Ph.D.Chief Quality & Technical OfficerMr. Matthew TreagusChief Information OfficerSophia BolhassanHead of Investor RelationsMs. Natalie Louise Walter (Age 51)General Counsel & Company Secretary Ms. Lisa JamesChief People OfficerDr. Kyriacos Mitrophanous Ph.D.Chief Innovation OfficerMs. Kati HudsonHead of Intellectual Property and Contracts More Insider Trading Tools from MarketBeat Related Companies Genus Insider Selling Faron Pharmaceuticals Oy Insider Selling Bioventix Insider Selling 4basebio Insider Selling Sareum Insider Selling Arecor Therapeutics Insider Selling Poolbeg Pharma Insider Selling Oxford BioDynamics Insider Selling IXICO Insider Selling Fusion Antibodies Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (LON:OXB) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut with the old (A.I.) - In with the new (E.I.)One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxford Biomedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
